M-sense
App to treat and know more about migraines.
| EUR | 2018 | 2019 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | (34 %) |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | (141 %) | (312 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
M-sense, developed by the Berlin-based startup Newsenselab GmbH, operates in the digital therapeutics market, offering a certified medical application to address migraines and headaches. Founded in 2015 by Markus Dahlem, Simon Scholler, and Martin Lysk, the company has leveraged its founders' expertise to create a mobile-based therapy solution. The executive team includes Markus Dahlem as CEO, Simon Scholler as Chief Product Officer, and Martin Lysk as CTO.
The company's business revolves around its primary product, the "M-sense Migräne" app, which functions as a digital health application (DiGA) in Germany. This allows doctors to prescribe the app, with costs reimbursed by all statutory health insurers in the country under the Digital Health Care Act (DVG). This prescription-based model forms a core part of its revenue stream. The app is designed for individuals suffering from migraines, providing them with tools to manage their condition.
The M-sense application offers personalized, non-drug therapy methods based on clinical guidelines. Its features include an intelligent headache diary for tracking attacks, medication use, and lifestyle factors to identify personal triggers. The platform provides users with personalized information and offers drug-free treatment methods such as relaxation techniques, physiotherapy exercises, and guidance on endurance sports to help prevent and relieve attacks. Newsenselab has engaged in clinical trials and research partnerships with institutions like Charité Universitätsmedizin Berlin to validate the effectiveness of its digital therapy. The company has secured funding through multiple rounds, including a Series A in December 2021, from investors such as High-Tech Gründerfonds (HTGF), IBB Ventures, and Noaber Foundation. In August 2022, the company underwent a merger/acquisition with glucura.
Keywords: digital therapeutics, migraine management, headache therapy, DiGA, digital health application, Newsenselab, Markus Dahlem, mobile health, prescription app, non-drug therapy, headache diary, trigger tracking, telemedicine, healthtech, Berlin startup, clinical trials, HTGF, IBB Ventures, glucura, Simon Scholler